Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Agios Pharmaceuticals (AGIO) over the last 8 years, with Q4 2025 value amounting to $5.5 million.

  • Agios Pharmaceuticals' Change in Receivables rose 45983.85% to $5.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.5 million, marking a year-over-year increase of 39792.15%. This contributed to the annual value of $6.5 million for FY2025, which is 39792.15% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Change in Receivables of $5.5 million as of Q4 2025, which was up 45983.85% from $43000.0 recorded in Q3 2025.
  • Agios Pharmaceuticals' Change in Receivables' 5-year high stood at $8.1 million during Q2 2021, with a 5-year trough of -$7.0 million in Q4 2021.
  • Moreover, its 5-year median value for Change in Receivables was $388000.0 (2022), whereas its average is $556684.2.
  • Over the last 5 years, Agios Pharmaceuticals' Change in Receivables had its largest YoY gain of 45983.85% in 2025, and its largest YoY loss of 21897.36% in 2025.
  • Agios Pharmaceuticals' Change in Receivables (Quarter) stood at -$7.0 million in 2021, then skyrocketed by 105.55% to $388000.0 in 2022, then skyrocketed by 321.13% to $1.6 million in 2023, then crashed by 39.35% to $991000.0 in 2024, then surged by 459.84% to $5.5 million in 2025.
  • Its last three reported values are $5.5 million in Q4 2025, $43000.0 for Q3 2025, and $1.6 million during Q2 2025.